IL-17 exhibits proinflammatory properties similar to those of tumor necrosis factor-α, particularly with respect to induction of other inflammatory effectors. In addition, IL-17 synergizes potently with other cytokines, placing it in the center of the in
Here we will examine the major cytokines currently in use or under evaluation for cancer therapy: interferon alfa, IL-2, GM-CSF, and interleukin-12 (IL-12).